ReVision Implant, a Belgian neurotechnology company developing a cortical visual prosthesis for people with severe blindness, has secured €4 million in an oversubscribed funding round backed by private investors.
The round included participation from existing investors as well as new backers, including European business leaders and medtech operators.
The funding builds on ReVision Implant’s existing support from public programmes, including several highly selective European Innovation Council grants such as the €2.4 million FlairVision project. The company is also supported by the Plug and Play and imec.istart incubators.
ReVision Implant is developing a brain-computer interface designed to restore functional vision in patients who cannot benefit from retinal or optic nerve-based therapies. By interfacing directly with the brain’s visual cortex, the system aims to bypass damage to the eye and optic nerve and enable patients to perceive and interpret visual information.
The company began building its own cleanroom infrastructure several months ago as part of preparations for future clinical trials and greater control over manufacturing and quality processes.
According to Frederik Ceyssens, CEO of ReVision Implant, the funding represents a key milestone as the company moves from development into the next phase of clinical and operational expansion.
We are investing in our own cleanroom environment to bring important manufacturing steps in-house, while expanding our team and advancing our regulatory compliance and clinical programme over the coming years. At the same time, we are continuing product development and strengthening our collaborations with other medtech companies as we move closer to bringing our technology to patients.
The company’s progress comes amid broader advances in neurotechnology and brain-computer interfaces, with growing interest in devices designed to help address conditions including blindness, paralysis, amputations, aphasia, and locked-in syndrome.
With the new funding secured, ReVision Implant is preparing for the next stage of clinical development and operational scale-up.
Would you like to write the first comment?
Login to post comments